PSA is kallikrein-3, a protease enzyme, that stimulates the growth of PCa [21], and the rise in PSA means a higher production of this tumor stimulator, which explains that the suppression of the tumor stimulator by ADT is associated with clinical benefits [22] and also explains why PSA is a marker for PCa tumor progression. This evidence concerns the gene KLK3 and neoplasm.